CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Ultimaster Tansei 80 MicronWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2766 Supraflex Cruz 60 Micron Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D006470 Hemorrhage NIH 0.50
D006331 Heart Diseases NIH 0.35

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population

The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).

NCT04500912 Cardiac D Cardiac Disease PCI High Bleeding Risk Device: Supraflex Cruz 60 Micron Device: Ultimaster Tansei 80 Micron
MeSH:Heart Diseases Hemorrhage

Primary Outcomes

Description: The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, myocardial infarction, target vessel revascularization, stroke and bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.

Measure: Net Adverse Clinical Endpoints (NACE)

Time: 1 year

Secondary Outcomes

Description: Major adverse cardiac and cerebral events (MACCE) defined as a composite of cardiac death, myocardial infarction, target vessel revascularization and stroke

Measure: Major adverse cardiac and cerebral events (MACCE)

Time: 1 year

Description: Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events

Measure: Major or clinically relevant non-major bleeding (MCB)

Time: 1 year

Description: Target Lesion Failure (TLF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target lesion revascularization

Measure: Target Lesion Failure (TLF)

Time: 1 year

Description: Target Vessel Failure (TVF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target vessel revascularization

Measure: Target vessel failure (TVF)

Time: 1 year

Description: The composite endpoint of cardiovascular death, myocardial infarction and stroke

Measure: The composite of cardiovascular death, myocardial infarction and stroke

Time: 1 year

Description: The composite of cardiovascular death, myocardial infarction, stroke and major bleed according to BARC 3 and 5

Measure: The composite of cardiovascular death, myocardial infarction, stroke and major bleed BARC 3 and 5

Time: 1 year

Description: Stent thrombosis according to the ARC definitions

Measure: Stent thrombosis

Time: 1 year

Description: Myocardial infarction.

Measure: Myocardial infarction

Time: 1 year

Description: Urgent target vessel revascularization.

Measure: Urgent target vessel revascularization

Time: 1 year

Description: Non-target vessel revascularization.

Measure: Non-target vessel revascularization

Time: 1 year

Description: Clinically indicated target vessel revascularization.

Measure: Clinically indicated target vessel revascularization

Time: 1 year

Description: Bleeding events

Measure: Bleeding events

Time: 1 year

Description: Transfusion rates both in patients with and/or without clinically detected over bleeding

Measure: Transfusion rates

Time: 1 year

Description: Event rates according to the PRECISE-DAPT score

Measure: Event rates according to the PRECISE-DAPT

Time: 1 year

Description: Procedural success.

Measure: Procedural success

Time: 1 year

Description: Device success.

Measure: Device success

Time: 1 year

No related HPO nodes (Using clinical trials)